{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:23:34Z","timestamp":1792023814263,"version":"4.4.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"DOI":"10.1038\/s41575-024-01031-x","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:52:48Z","timestamp":1737985968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preventing the progression of cirrhosis to decompensation and death"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-914X","authenticated-orcid":false,"given":"C\u00e0ndid","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-6382","authenticated-orcid":false,"given":"Dhiraj","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-0055","authenticated-orcid":false,"given":"Jaume","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"1031_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","volume":"68","author":"G D\u2019Amico","year":"2018","unstructured":"D\u2019Amico, G. et al. Clinical states of cirrhosis and competing risks. J. Hepatol. 68, 563\u2013576 (2018).","journal-title":"J. Hepatol."},{"key":"1031_CR2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva, C. et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393, 1597\u20131608 (2019). The first RCT to show that \u03b2-blockers prevent decompensation and improve survival in patients with compensated cirrhosis.","journal-title":"Lancet"},{"key":"1031_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","volume":"77","author":"C Villanueva","year":"2022","unstructured":"Villanueva, C. et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J. Hepatol. 77, 1014\u20131025 (2022). A recent individual patient data meta-analysis showing that carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis.","journal-title":"J. Hepatol."},{"key":"1031_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1309\/AJCP2T2OHTAPBTMP","volume":"137","author":"P Hytiroglou","year":"2012","unstructured":"Hytiroglou, P. et al. Beyond \u201ccirrhosis\u201d: a proposal from the International Liver Pathology Study Group. Am. J. Clin. Pathol. 137, 5\u20139 (2012).","journal-title":"Am. J. Clin. Pathol."},{"key":"1031_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.dld.2021.09.004","volume":"54","author":"N Asesio","year":"2022","unstructured":"Asesio, N. et al. Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis. Dig. Liver Dis. 54, 645\u2013653 (2022).","journal-title":"Dig. Liver Dis."},{"key":"1031_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jhep.2023.12.028","volume":"80","author":"M Jachs","year":"2024","unstructured":"Jachs, M. et al. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient. J. Hepatol. 80, 744\u2013752 (2024).","journal-title":"J. Hepatol."},{"key":"1031_CR7","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1007\/s10620-021-07334-2","volume":"67","author":"A Jindal","year":"2022","unstructured":"Jindal, A., Sarin, S. K., Kumar, M. & Kumar, G. Clinical outcomes in patients with advanced chronic liver disease and hepatic venous pressure gradient \u226410 mm Hg. Dig. Dis. Sci. 67, 5280\u20135289 (2022).","journal-title":"Dig. Dis. Sci."},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12072-021-10280-w","volume":"16","author":"A Jindal","year":"2022","unstructured":"Jindal, A. et al. Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria. Hepatol. Int. 16, 89\u201398 (2022).","journal-title":"Hepatol. Int."},{"key":"1031_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00535-023-02049-9","volume":"59","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi, T. et al. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography. J. Gastroenterol. 59, 56\u201365 (2024).","journal-title":"J. Gastroenterol."},{"key":"1031_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/apt.17699","volume":"58","author":"H Lin","year":"2023","unstructured":"Lin, H. et al. Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: a competing risk analysis. Aliment. Pharmacol. Ther. 58, 920\u2013928 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1031_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/liv.15161","volume":"42","author":"ARP Schneider","year":"2022","unstructured":"Schneider, A. R. P. et al. Early prediction of decompensation (EPOD) score: non-invasive determination of cirrhosis decompensation risk. Liver Int. 42, 640\u2013650 (2022).","journal-title":"Liver Int."},{"key":"1031_CR12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","volume":"165","author":"G Semmler","year":"2023","unstructured":"Semmler, G. et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease. Gastroenterology 165, 1041\u20131052 (2023).","journal-title":"Gastroenterology"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.cgh.2022.03.015","volume":"21","author":"JE Shearer","year":"2023","unstructured":"Shearer, J. E., Jones, R., Parker, R., Ferguson, J. & Rowe, I. A. The natural history of advanced chronic liver disease defined by transient elastography. Clin. Gastroenterol. Hepatol. 21, 694\u2013703.e8 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/liv.15632","volume":"43","author":"BG Song","year":"2023","unstructured":"Song, B. G. et al. Validation of non-invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII. Liver Int. 43, 1966\u20131974 (2023).","journal-title":"Liver Int."},{"key":"1031_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jhep.2024.02.019","volume":"81","author":"KH Thorhauge","year":"2024","unstructured":"Thorhauge, K. H. et al. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J. Hepatol. 81, 23\u201332 (2024).","journal-title":"J. Hepatol."},{"key":"1031_CR16","doi-asserted-by":"publisher","unstructured":"Wong, Y. J. et al. Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000000891 (2024).","DOI":"10.1097\/HEP.0000000000000891"},{"key":"1031_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3350\/cmh.2022.0181","volume":"29","author":"YJ Wong","year":"2023","unstructured":"Wong, Y. J. et al. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients. Clin. Mol. Hepatol. 29, 135\u2013145 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"1031_CR18","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s10620-021-07168-y","volume":"67","author":"Y Hai","year":"2022","unstructured":"Hai, Y., Chong, W., Eisenbrey, J. R. & Forsberg, F. Network meta-analysis: noninvasive imaging modalities for identifying clinically significant portal hypertension. Dig. Dis. Sci. 67, 3313\u20133326 (2022).","journal-title":"Dig. Dis. Sci."},{"key":"1031_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","volume":"144","author":"A Berzigotti","year":"2013","unstructured":"Berzigotti, A. et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 144, 102\u2013111.e1 (2013).","journal-title":"Gastroenterology"},{"key":"1031_CR20","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMoa044456","volume":"353","author":"RJ Groszmann","year":"2005","unstructured":"Groszmann, R. J. et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N. Engl. J. Med. 353, 2254\u20132261 (2005). A seminal RCT defining CSPH.","journal-title":"N. Engl. J. Med."},{"key":"1031_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","volume":"133","author":"C Ripoll","year":"2007","unstructured":"Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133, 481\u2013488 (2007).","journal-title":"Gastroenterology"},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00535-010-0360-z","volume":"46","author":"A Berzigotti","year":"2011","unstructured":"Berzigotti, A. et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J. Gastroenterol. 46, 687\u2013695 (2011).","journal-title":"J. Gastroenterol."},{"key":"1031_CR23","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","volume":"383","author":"EA Tsochatzis","year":"2014","unstructured":"Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet 383, 1749\u20131761 (2014).","journal-title":"Lancet"},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-0036-1583202","volume":"36","author":"V Arroyo","year":"2016","unstructured":"Arroyo, V. & Jalan, R. Acute-on-chronic liver failure: definition, diagnosis, and clinical characteristics. Semin. Liver Dis. 36, 109\u2013116 (2016).","journal-title":"Semin. Liver Dis."},{"key":"1031_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/HEP.0000000000000652","volume":"79","author":"G D\u2019Amico","year":"2024","unstructured":"D\u2019Amico, G. et al. Further decompensation in cirrhosis: results of a large multicenter cohort study supporting Baveno VII statements. Hepatology 79, 869\u2013881 (2024).","journal-title":"Hepatology"},{"key":"1031_CR26","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1111\/liv.15937","volume":"44","author":"M Garcia-Guix","year":"2024","unstructured":"Garcia-Guix, M. et al. Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: the role of portal hypertension and HVPG changes. Liver Int. 44, 1971\u20131989 (2024).","journal-title":"Liver Int."},{"key":"1031_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2021.06.018","volume":"76","author":"G D\u2019Amico","year":"2022","unstructured":"D\u2019Amico, G., Bernardi, M. & Angeli, P. Towards a new definition of decompensated cirrhosis. J. Hepatol. 76, 202\u2013207 (2022).","journal-title":"J. Hepatol."},{"key":"1031_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jhep.2023.12.005","volume":"80","author":"M Tonon","year":"2024","unstructured":"Tonon, M. et al. A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis. J. Hepatol. 80, 603\u2013609 (2024).","journal-title":"J. Hepatol."},{"key":"1031_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jhep.2024.01.039","volume":"80","author":"F Artru","year":"2024","unstructured":"Artru, F. & Reiberger, T. One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis. J. Hepatol. 80, 537\u2013539 (2024).","journal-title":"J. Hepatol."},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","volume":"144","author":"R Moreau","year":"2013","unstructured":"Moreau, R. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426\u20131437.e9 (2013).","journal-title":"Gastroenterology"},{"key":"1031_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","volume":"73","author":"J Trebicka","year":"2020","unstructured":"Trebicka, J. et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J. Hepatol. 73, 842\u2013854 (2020).","journal-title":"J. Hepatol."},{"key":"1031_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis, R. et al. Baveno VII \u2013 Renewing consensus in portal hypertension. J. Hepatol. 76, 959\u2013974 (2022). A comprehensive consensus document that has led to change in clinical practice and encouraged further research.","journal-title":"J. Hepatol."},{"key":"1031_CR33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","volume":"160","author":"DC Rockey","year":"2021","unstructured":"Rockey, D. C. & Friedman, S. L. Fibrosis regression after eradication of hepatitis C virus: from bench to bedside. Gastroenterology 160, 1502\u20131520.e1 (2021).","journal-title":"Gastroenterology"},{"key":"1031_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 391, 299\u2013310 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal, A. J. et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med. 391, 311\u2013319 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR37","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","volume":"62","author":"J Bosch","year":"2015","unstructured":"Bosch, J., Groszmann, R. J. & Shah, V. H. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J. Hepatol. 62, S121\u2013S130 (2015).","journal-title":"J. Hepatol."},{"key":"1031_CR38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jhep.2007.03.014","volume":"47","author":"J Gracia-Sancho","year":"2007","unstructured":"Gracia-Sancho, J. et al. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J. Hepatol. 47, 220\u2013227 (2007).","journal-title":"J. Hepatol."},{"key":"1031_CR39","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","volume":"64","author":"G Marrone","year":"2015","unstructured":"Marrone, G. et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut 64, 1434\u20131443 (2015).","journal-title":"Gut"},{"key":"1031_CR40","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.21785","volume":"46","author":"M Fernandez","year":"2007","unstructured":"Fernandez, M. et al. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 46, 1208\u20131217 (2007).","journal-title":"Hepatology"},{"key":"1031_CR41","doi-asserted-by":"publisher","first-page":"G980","DOI":"10.1152\/ajpgi.00336.2005","volume":"290","author":"JG Abraldes","year":"2006","unstructured":"Abraldes, J. G. et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G980\u2013G987 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1031_CR42","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep.1840080532","volume":"8","author":"RW Schrier","year":"1988","unstructured":"Schrier, R. W. et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151\u20131157 (1988).","journal-title":"Hepatology"},{"key":"1031_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41575-021-00520-7","volume":"19","author":"A Albillos","year":"2022","unstructured":"Albillos, A. et al. Cirrhosis-associated immune dysfunction. Nat. Rev. Gastroenterol. Hepatol. 19, 112\u2013134 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1031_CR44","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/hep.28740","volume":"64","author":"J Claria","year":"2016","unstructured":"Claria, J. et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 64, 1249\u20131264 (2016).","journal-title":"Hepatology"},{"key":"1031_CR45","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","volume":"67","author":"R Wiest","year":"2017","unstructured":"Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S. & Jalan, R. Targeting the gut\u2013liver axis in liver disease. J. Hepatol. 67, 1084\u20131103 (2017).","journal-title":"J. Hepatol."},{"key":"1031_CR46","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/lt.23495","volume":"18","author":"P Tandon","year":"2012","unstructured":"Tandon, P. et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 18, 1209\u20131216 (2012).","journal-title":"Liver Transpl."},{"key":"1031_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217\u2013231 (2006). An important study defining the different stages of cirrhosis.","journal-title":"J. Hepatol."},{"key":"1031_CR48","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jhep.2014.02.024","volume":"60","author":"A Colecchia","year":"2014","unstructured":"Colecchia, A. et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J. Hepatol. 60, 1158\u20131164 (2014).","journal-title":"J. Hepatol."},{"key":"1031_CR49","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/cid\/cit768","volume":"58","author":"L Perez-Latorre","year":"2014","unstructured":"Perez-Latorre, L. et al. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography. Clin. Infect. Dis. 58, 713\u2013718 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"1031_CR50","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3109\/00365521.2014.964758","volume":"50","author":"MT Kitson","year":"2015","unstructured":"Kitson, M. T. et al. Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications. Scand. J. Gastroenterol. 50, 462\u2013469 (2015).","journal-title":"Scand. J. Gastroenterol."},{"key":"1031_CR51","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/hep.30885","volume":"71","author":"M Mandorfer","year":"2020","unstructured":"Mandorfer, M. et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology 71, 1023\u20131036 (2020).","journal-title":"Hepatology"},{"key":"1031_CR52","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/hep.31576","volume":"73","author":"L Calzadilla-Bertot","year":"2020","unstructured":"Calzadilla-Bertot, L. et al. ABIDE: an accurate predictive model of liver decompensation in patients with nonalcoholic fatty liver-related cirrhosis. Hepatology 73, 2238\u20132250 (2020).","journal-title":"Hepatology"},{"key":"1031_CR53","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jhep.2021.05.008","volume":"75","author":"R Younes","year":"2021","unstructured":"Younes, R. et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J. Hepatol. 75, 786\u2013794 (2021).","journal-title":"J. Hepatol."},{"key":"1031_CR54","doi-asserted-by":"publisher","unstructured":"Thiele, M. et al. Noninvasive assessment of hepatic decompensation. Hepatology https:\/\/doi.org\/10.1097\/hep.0000000000000618 (2023).","DOI":"10.1097\/hep.0000000000000618"},{"key":"1031_CR55","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ajg.2011.456","volume":"107","author":"V Hernandez-Gea","year":"2012","unstructured":"Hernandez-Gea, V. et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with \u03b2-blockers. Am. J. Gastroenterol. 107, 418\u2013427 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"1031_CR56","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cgh.2019.05.050","volume":"18","author":"L Turco","year":"2020","unstructured":"Turco, L. et al. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis. Clin. Gastroenterol. Hepatol. 18, 313\u2013327.e6 (2020). A well-conducted meta-analysis showing improved outcomes in patients who had a reduction in portal pressure with NSBBs.","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR57","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.14309\/ajg.0000000000000653","volume":"115","author":"A Jindal","year":"2020","unstructured":"Jindal, A., Bhardwaj, A., Kumar, G. & Sarin, S. K. Clinical decompensation and outcomes in patients with compensated cirrhosis and a hepatic venous pressure gradient \u226520\u2009mm Hg. Am. J. Gastroenterol. 115, 1624\u20131633 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"1031_CR58","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cgh.2015.04.013","volume":"13","author":"S Lens","year":"2015","unstructured":"Lens, S. et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin. Gastroenterol. Hepatol. 13, 1846\u20131853.e1 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3109\/00365521.2012.711848","volume":"48","author":"D Rincon","year":"2013","unstructured":"Rincon, D. et al. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand. J. Gastroenterol. 48, 487\u2013495 (2013).","journal-title":"Scand. J. Gastroenterol."},{"key":"1031_CR60","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2021.12.038","volume":"76","author":"B Scheiner","year":"2022","unstructured":"Scheiner, B. et al. Factor VIII\/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J. Hepatol. 76, 1090\u20131099 (2022).","journal-title":"J. Hepatol."},{"key":"1031_CR61","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/jhep.2003.50133","volume":"37","author":"JG Abraldes","year":"2003","unstructured":"Abraldes, J. G. et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37, 902\u2013908 (2003).","journal-title":"Hepatology"},{"key":"1031_CR62","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","volume":"131","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico, G., Garcia-Pagan, J. C., Luca, A. & Bosch, J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 131, 1611\u20131624 (2006).","journal-title":"Gastroenterology"},{"key":"1031_CR63","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S0140-6736(95)91740-3","volume":"346","author":"F Feu","year":"1995","unstructured":"Feu, F. et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 346, 1056\u20131059 (1995).","journal-title":"Lancet"},{"key":"1031_CR64","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1002\/hep.32087","volume":"74","author":"J Bosch","year":"2021","unstructured":"Bosch, J. et al. A machine learning approach to liver histological evaluation predicts clinically significant portal hypertension in NASH cirrhosis. Hepatology 74, 3146\u20133160 (2021).","journal-title":"Hepatology"},{"key":"1031_CR65","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison, S. A. et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 155, 1140\u20131153 (2018).","journal-title":"Gastroenterology"},{"key":"1031_CR66","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal, A. J. et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 70, 1913\u20131927 (2019). A large data set from a randomized controlled drug trial showing that a number of invasive and noninvasive tests predict decompensation.","journal-title":"Hepatology"},{"key":"1031_CR67","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.cgh.2021.10.023","volume":"20","author":"O Bassegoda","year":"2022","unstructured":"Bassegoda, O. et al. Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease. Clin. Gastroenterol. Hepatol. 20, 2276\u20132286.e6 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR68","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2019.04.026","volume":"17","author":"JG Abraldes","year":"2019","unstructured":"Abraldes, J. G. & Garcia-Tsao, G. Simple clinical tools to predict decompensation in patients with compensated cirrhosis: an unmet need. Clin. Gastroenterol. Hepatol. 17, 2179\u20132181 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR69","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.cgh.2019.01.042","volume":"17","author":"IN Guha","year":"2019","unstructured":"Guha, I. N. et al. Validation of a model for identification of patients with compensated cirrhosis at high risk of decompensation. Clin. Gastroenterol. Hepatol. 17, 2330\u20132338.e1 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR70","doi-asserted-by":"publisher","first-page":"101062","DOI":"10.1016\/j.jhepr.2024.101062","volume":"6","author":"M Pearson","year":"2024","unstructured":"Pearson, M. et al. Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality. JHEP Rep. 6, 101062 (2024).","journal-title":"JHEP Rep."},{"key":"1031_CR71","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/v15061251","volume":"15","author":"P Fern\u00e1ndez-Alvarez","year":"2023","unstructured":"Fern\u00e1ndez-Alvarez, P. et al. Dynamic changes in non-invasive markers of liver fibrosis are predictors of liver events after SVR in HCV patients. Viruses 15, 1251 (2023).","journal-title":"Viruses"},{"key":"1031_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128774","volume":"10","author":"G Sebastiani","year":"2015","unstructured":"Sebastiani, G. et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS ONE 10, e0128774 (2015).","journal-title":"PLoS ONE"},{"key":"1031_CR73","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","volume":"73","author":"H Hagstrom","year":"2020","unstructured":"Hagstrom, H., Talback, M., Andreasson, A., Walldius, G. & Hammar, N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J. Hepatol. 73, 1023\u20131029 (2020).","journal-title":"J. Hepatol."},{"key":"1031_CR74","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE Mozes","year":"2023","unstructured":"Mozes, F. E. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol. Hepatol. 8, 704\u2013713 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1031_CR75","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.cgh.2019.10.041","volume":"18","author":"JE Eaton","year":"2020","unstructured":"Eaton, J. E. et al. Changes in liver stiffness, measured by magnetic resonance elastography, associated with hepatic decompensation in patients with primary sclerosing cholangitis. Clin. Gastroenterol. Hepatol. 18, 1576\u20131583.e1 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR76","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.cgh.2020.09.044","volume":"19","author":"T Gidener","year":"2020","unstructured":"Gidener, T. et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin. Gastroenterol. Hepatol. 19, 1915\u20131924.e6 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR77","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/liv.14593","volume":"40","author":"MAT Han","year":"2020","unstructured":"Han, M. A. T. et al. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: a multicenter study. Liver Int. 40, 2242\u20132251 (2020).","journal-title":"Liver Int."},{"key":"1031_CR78","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/MCG.0000000000001433","volume":"55","author":"KT Osman","year":"2021","unstructured":"Osman, K. T. et al. Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis. J. Clin. Gastroenterol. 55, 449\u2013457 (2021).","journal-title":"J. Clin. Gastroenterol."},{"key":"1031_CR79","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jhep.2011.01.051","volume":"55","author":"MA Robic","year":"2011","unstructured":"Robic, M. A. et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J. Hepatol. 55, 1017\u20131024 (2011).","journal-title":"J. Hepatol."},{"key":"1031_CR80","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.14309\/ajg.0000000000001887","volume":"117","author":"E Dajti","year":"2022","unstructured":"Dajti, E. et al. A combined Baveno VII and spleen stiffness algorithm to improve the noninvasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease. Am. J. Gastroenterol. 117, 1825\u20131833 (2022).","journal-title":"Am. J. Gastroenterol."},{"key":"1031_CR81","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2468-1253(23)00150-4","volume":"8","author":"E Dajti","year":"2023","unstructured":"Dajti, E. et al. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis. Lancet Gastroenterol. Hepatol. 8, 816\u2013828 (2023). A recent individual patient data meta-analysis showing that splenic stiffness measurements can improve the precision of Baveno VII grey zone criteria in determining CSPH.","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1031_CR82","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.cgh.2023.08.004","volume":"22","author":"M Pons","year":"2023","unstructured":"Pons, M. et al. Point-of-care noninvasive prediction of liver-related events in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 22, 1637\u20131645.e9 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR83","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","volume":"79","author":"DE Kaplan","year":"2023","unstructured":"Kaplan, D. E. et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 79, 1180\u20131211 (2023). A recent clinical practice guidance document that is likely to result in change in clinical practice.","journal-title":"Hepatology"},{"key":"1031_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1291-3","volume":"15","author":"N Merchante","year":"2015","unstructured":"Merchante, N. et al. Progression of liver stiffness predicts clinical events in HIV\/HCV-coinfected patients with compensated cirrhosis. BMC Infect. Dis. 15, 557 (2015).","journal-title":"BMC Infect. Dis."},{"key":"1031_CR85","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","volume":"19","author":"S Petta","year":"2021","unstructured":"Petta, S. et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin. Gastroenterol. Hepatol. 19, 806\u2013815.e5 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR86","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jhep.2020.10.004","volume":"74","author":"D Costa","year":"2021","unstructured":"Costa, D. et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J. Hepatol. 74, 819\u2013828 (2021).","journal-title":"J. Hepatol."},{"key":"1031_CR87","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1097\/HEP.0000000000000316","volume":"77","author":"O Nicoar\u0103-Farc\u0103u","year":"2023","unstructured":"Nicoar\u0103-Farc\u0103u, O. et al. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis. Hepatology 77, 2052\u20132062 (2023).","journal-title":"Hepatology"},{"key":"1031_CR88","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jhep.2024.03.005","volume":"81","author":"M Jachs","year":"2024","unstructured":"Jachs, M. et al. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta. J. Hepatol. 81, 248\u2013257 (2024).","journal-title":"J. Hepatol."},{"key":"1031_CR89","doi-asserted-by":"publisher","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","volume":"116","author":"M Pons","year":"2021","unstructured":"Pons, M. et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am. J. Gastroenterol. 116, 723\u2013732 (2021). This study defines the rule of five for ruling in and out cACLD and CSPH, and the source of the ANTICIPATE model for improving precision in MASLD.","journal-title":"Am. J. Gastroenterol."},{"key":"1031_CR90","doi-asserted-by":"publisher","unstructured":"Dajti, E. et al. Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: a post-hoc analysis of the PREDESCI trial. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.014 (2024).","DOI":"10.1016\/j.jhep.2024.09.014"},{"key":"1031_CR91","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.jhep.2024.06.028","volume":"81","author":"YP Mendoza","year":"2024","unstructured":"Mendoza, Y. P. et al. Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression. J. Hepatol. 81, 983\u2013994 (2024).","journal-title":"J. Hepatol."},{"key":"1031_CR92","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMra1300575","volume":"372","author":"DC Rockey","year":"2015","unstructured":"Rockey, D. C., Bell, P. D. & Hill, J. A. Fibrosis \u2013 a common pathway to organ injury and failure. N. Engl. J. Med. 372, 1138\u20131149 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR93","doi-asserted-by":"crossref","unstructured":"Pinzani, M. in Portal Hypertension VII (ed. de Franchis, R.) 175\u2013182 (Springer, 2022).","DOI":"10.1007\/978-3-031-08552-9_16"},{"key":"1031_CR94","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41575-023-00796-x","volume":"20","author":"PN Brennan","year":"2023","unstructured":"Brennan, P. N. et al. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. Nat. Rev. Gastroenterol. Hepatol. 20, 679\u2013688 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1031_CR95","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee, Y. et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 17, 1040\u20131060.e11 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR96","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","volume":"153","author":"S Lens","year":"2017","unstructured":"Lens, S. et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 153, 1273\u20131283.e1 (2017).","journal-title":"Gastroenterology"},{"key":"1031_CR97","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","volume":"151","author":"V Di Marco","year":"2016","unstructured":"Di Marco, V. et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 151, 130\u2013139.e2 (2016).","journal-title":"Gastroenterology"},{"key":"1031_CR98","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cld.2021.01.003","volume":"25","author":"M Mandorfer","year":"2021","unstructured":"Mandorfer, M. & Simbrunner, B. Prevention of first decompensation in advanced chronic liver disease. Clin. Liver Dis. 25, 291\u2013310 (2021).","journal-title":"Clin. Liver Dis."},{"key":"1031_CR99","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.23744","volume":"52","author":"TR Morgan","year":"2010","unstructured":"Morgan, T. R. et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52, 833\u2013844 (2010).","journal-title":"Hepatology"},{"key":"1031_CR100","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","volume":"73","author":"S Lens","year":"2020","unstructured":"Lens, S. et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J. Hepatol. 73, 1415\u20131424 (2020).","journal-title":"J. Hepatol."},{"key":"1031_CR101","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0039-1696639","volume":"40","author":"P Tandon","year":"2020","unstructured":"Tandon, P. & Berzigotti, A. Management of lifestyle factors in individuals with cirrhosis: a pragmatic review. Semin. Liver Dis. 40, 20\u201328 (2020).","journal-title":"Semin. Liver Dis."},{"key":"1031_CR102","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388\u20131402 (2016).","journal-title":"J. Hepatol."},{"key":"1031_CR103","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/hep.20127","volume":"39","author":"A Monto","year":"2004","unstructured":"Monto, A. et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 39, 826\u2013834 (2004).","journal-title":"Hepatology"},{"key":"1031_CR104","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jhep.2019.05.020","volume":"71","author":"R Parker","year":"2019","unstructured":"Parker, R. et al. Natural history of histologically proven alcohol-related liver disease: a systematic review. J. Hepatol. 71, 586\u2013593 (2019).","journal-title":"J. Hepatol."},{"key":"1031_CR105","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","volume":"111","author":"J Vorobioff","year":"1996","unstructured":"Vorobioff, J. et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 111, 701\u2013709 (1996).","journal-title":"Gastroenterology"},{"key":"1031_CR106","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/hep.24418","volume":"54","author":"A Berzigotti","year":"2011","unstructured":"Berzigotti, A. et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 54, 555\u2013561 (2011).","journal-title":"Hepatology"},{"key":"1031_CR107","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1053\/j.gastro.2009.05.007","volume":"137","author":"JE Everhart","year":"2009","unstructured":"Everhart, J. E. et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 137, 549\u2013557 (2009).","journal-title":"Gastroenterology"},{"key":"1031_CR108","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/hep.28992","volume":"65","author":"A Berzigotti","year":"2017","unstructured":"Berzigotti, A. et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology 65, 1293\u20131305 (2017).","journal-title":"Hepatology"},{"key":"1031_CR109","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/hep.32049","volume":"74","author":"JC Lai","year":"2021","unstructured":"Lai, J. C. et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 74, 1611\u20131644 (2021). This practice-changing guideline highlights the potential issues associated with sarcopenia and nutritional decline in ACLD.","journal-title":"Hepatology"},{"key":"1031_CR110","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1097\/HEP.0000000000000263","volume":"77","author":"L Castera","year":"2023","unstructured":"Castera, L. & Cusi, K. Diabetes and cirrhosis: current concepts on diagnosis and management. Hepatology 77, 2128\u20132146 (2023).","journal-title":"Hepatology"},{"key":"1031_CR111","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/liv.13115","volume":"36","author":"L Elkrief","year":"2016","unstructured":"Elkrief, L. et al. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 36, 936\u2013948 (2016).","journal-title":"Liver Int."},{"key":"1031_CR112","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","volume":"398","author":"P Gines","year":"2021","unstructured":"Gines, P. et al. Liver cirrhosis. Lancet 398, 1359\u20131376 (2021).","journal-title":"Lancet"},{"key":"1031_CR113","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"1031_CR114","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/hep.31646","volume":"73","author":"PG Northup","year":"2021","unstructured":"Northup, P. G. et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 73, 366\u2013413 (2021).","journal-title":"Hepatology"},{"key":"1031_CR115","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.27546","volume":"61","author":"F Nery","year":"2015","unstructured":"Nery, F. et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 61, 660\u2013667 (2015). A large data set describing the natural history of\u00a0PVT in cirrhosis.","journal-title":"Hepatology"},{"key":"1031_CR116","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jhep.2021.07.020","volume":"75","author":"F Turon","year":"2021","unstructured":"Turon, F. et al. Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors. J. Hepatol. 75, 1367\u20131376 (2021).","journal-title":"J. Hepatol."},{"key":"1031_CR117","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12072-018-9918-2","volume":"13","author":"U Iqbal","year":"2019","unstructured":"Iqbal, U. et al. Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis. Hepatol. Int. 13, 84\u201390 (2019).","journal-title":"Hepatol. Int."},{"key":"1031_CR118","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","volume":"79","author":"A Guerrero","year":"2023","unstructured":"Guerrero, A. et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis. J. Hepatol. 79, 69\u201378 (2023). A recent meta-analysis showing the potential benefits of anticoagulation in cirrhosis and PVT.","journal-title":"J. Hepatol."},{"key":"1031_CR119","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/s-2006-951603","volume":"26","author":"J Bosch","year":"2006","unstructured":"Bosch, J., Garcia-Pagan, J. C., Berzigotti, A. & Abraldes, J. G. Measurement of portal pressure and its role in the management of chronic liver disease. Semin. Liver Dis. 26, 348\u2013362 (2006).","journal-title":"Semin. Liver Dis."},{"key":"1031_CR120","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jhep.2019.07.007","volume":"71","author":"E Reverter","year":"2019","unstructured":"Reverter, E. et al. The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. J. Hepatol. 71, 942\u2013950 (2019).","journal-title":"J. Hepatol."},{"key":"1031_CR121","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/j.jhepr.2022.100442","volume":"4","author":"J Chang","year":"2022","unstructured":"Chang, J. et al. Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score. JHEP Rep. 4, 100442 (2022).","journal-title":"JHEP Rep."},{"key":"1031_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s13017-023-00498-4","volume":"18","author":"R Manzano-Nunez","year":"2023","unstructured":"Manzano-Nunez, R. et al. Unlocking the potential of TIPS placement as a bridge to elective and emergency surgery in cirrhotic patients: a meta-analysis and future directions for endovascular resuscitation in acute care surgery. World J. Emerg. Surg. 18, 30 (2023).","journal-title":"World J. Emerg. Surg."},{"key":"1031_CR123","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/gutjnl-2015-310275","volume":"66","author":"P Nahon","year":"2017","unstructured":"Nahon, P. et al. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut 66, 330\u2013341 (2017).","journal-title":"Gut"},{"key":"1031_CR124","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2021.04.022","volume":"75","author":"C Villanueva","year":"2021","unstructured":"Villanueva, C. et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. J. Hepatol. 75, 589\u2013599 (2021). This study highlights the importance of bacterial infections in the transition from compensated to decompensated cirrhosis in the PREDESCI cohort.","journal-title":"J. Hepatol."},{"key":"1031_CR125","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hep.28264","volume":"63","author":"C Villanueva","year":"2016","unstructured":"Villanueva, C. et al. Development of hyperdynamic circulation and response to \u03b2-blockers in compensated cirrhosis with portal hypertension. Hepatology 63, 197\u2013206 (2016).","journal-title":"Hepatology"},{"key":"1031_CR126","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2020.03.048","volume":"73","author":"E Alvarado-Tapias","year":"2020","unstructured":"Alvarado-Tapias, E. et al. Short-term hemodynamic effects of \u03b2-blockers influence survival of patients with decompensated cirrhosis. J. Hepatol. 73, 829\u2013841 (2020).","journal-title":"J. Hepatol."},{"key":"1031_CR127","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2016.01.022","volume":"64","author":"J Trebicka","year":"2016","unstructured":"Trebicka, J. et al. Assessment of response to beta-blockers by expression of \u03b2Arr2 and RhoA\/ROCK2 in antrum mucosa in cirrhotic patients. J. Hepatol. 64, 1265\u20131273 (2016).","journal-title":"J. Hepatol."},{"key":"1031_CR128","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/hep.1840050120","volume":"5","author":"RJ Kroeger","year":"1985","unstructured":"Kroeger, R. J. & Groszmann, R. J. Increased portal venous resistance hinders portal pressure reduction during the administration of \u03b2-adrenergic blocking agents in a portal hypertensive model. Hepatology 5, 97\u2013101 (1985).","journal-title":"Hepatology"},{"key":"1031_CR129","doi-asserted-by":"publisher","first-page":"9566","DOI":"10.3748\/wjg.v21.i32.9566","volume":"21","author":"Q Ding","year":"2015","unstructured":"Ding, Q., Tian, X. G., Li, Y., Wang, Q. Z. & Zhang, C. Q. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. World J. Gastroenterol. 21, 9566\u20139576 (2015).","journal-title":"World J. Gastroenterol."},{"key":"1031_CR130","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.12659\/MSM.913118","volume":"24","author":"L Ling","year":"2018","unstructured":"Ling, L., Li, G., Meng, D., Wang, S. & Zhang, C. Carvedilol ameliorates intrahepatic angiogenesis, sinusoidal remodeling and portal pressure in cirrhotic rats. Med. Sci. Monit. 24, 8290\u20138297 (2018).","journal-title":"Med. Sci. Monit."},{"key":"1031_CR131","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hep.510310109","volume":"31","author":"M Perez-Paramo","year":"2000","unstructured":"Perez-Paramo, M. et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 31, 43\u201348 (2000).","journal-title":"Hepatology"},{"key":"1031_CR132","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1038\/ajg.2009.457","volume":"104","author":"M Senzolo","year":"2009","unstructured":"Senzolo, M. et al. Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding? Am. J. Gastroenterol. 104, 3115\u20133116 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"1031_CR133","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A. & Bosch, J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 65, 310\u2013335 (2017).","journal-title":"Hepatology"},{"key":"1031_CR134","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","volume":"2","author":"SG Rodrigues","year":"2020","unstructured":"Rodrigues, S. G., Mendoza, Y. P. & Bosch, J. Beta-blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep. 2, 100063 (2020).","journal-title":"JHEP Rep."},{"key":"1031_CR135","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/hep.30220","volume":"69","author":"M Sharma","year":"2019","unstructured":"Sharma, M. et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis. Hepatology 69, 1657\u20131675 (2019).","journal-title":"Hepatology"},{"key":"1031_CR136","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/HEP.0000000000000342","volume":"78","author":"IA Rowe","year":"2023","unstructured":"Rowe, I. A. et al. Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: a Bayesian reanalysis of the PREDESCI trial. Hepatology 78, 530\u2013539 (2023).","journal-title":"Hepatology"},{"key":"1031_CR137","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/hep.32737","volume":"77","author":"M Serper","year":"2023","unstructured":"Serper, M. et al. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: a national cohort study. Hepatology 77, 489\u2013500 (2023).","journal-title":"Hepatology"},{"key":"1031_CR138","unstructured":"National Institute for Health and Care Excellence. Cirrhosis in Over 16s: Assessment and Management (NICE, 2023)."},{"key":"1031_CR139","doi-asserted-by":"publisher","first-page":"S627","DOI":"10.1016\/S0168-8278(22)01571-9","volume":"77","author":"A Brujats","year":"2022","unstructured":"Brujats, A. et al. Portal pressure decreasing effect of beta blockers in cirrhosis with clinically significant portal hypertension, according to the components of metabolic syndrome (Poster). J. Hepatol. 77, S627 (2022).","journal-title":"J. Hepatol."},{"key":"1031_CR140","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/flgastro-2023-102430","volume":"14","author":"D Mansour","year":"2023","unstructured":"Mansour, D. et al. British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis \u2013 part 1: compensated cirrhosis. Frontline Gastroenterol. 14, 453\u2013461 (2023).","journal-title":"Frontline Gastroenterol."},{"key":"1031_CR141","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","volume":"57","author":"JC Garcia-Pagan","year":"2012","unstructured":"Garcia-Pagan, J. C., Gracia-Sancho, J. & Bosch, J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J. Hepatol. 57, 458\u2013461 (2012).","journal-title":"J. Hepatol."},{"key":"1031_CR142","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/apt.17824","volume":"59","author":"C Villanueva","year":"2024","unstructured":"Villanueva, C. et al. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. Aliment. Pharmacol. Ther. 59, 306\u2013321 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1031_CR143","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/hep.23689","volume":"51","author":"J Bosch","year":"2010","unstructured":"Bosch, J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 51, 2214\u20132218 (2010).","journal-title":"Hepatology"},{"key":"1031_CR144","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/MEG.0b013e3283367a99","volume":"22","author":"D Tripathi","year":"2010","unstructured":"Tripathi, D. & Hayes, P. C. The role of carvedilol in the management of portal hypertension. Eur. J. Gastroenterol. Hepatol. 22, 905\u2013911 (2010).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1031_CR145","first-page":"G205","volume":"250","author":"E Sikuler","year":"1986","unstructured":"Sikuler, E. & Groszmann, R. J. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am. J. Physiol. 250, G205\u2013G212 (1986).","journal-title":"Am. J. Physiol."},{"key":"1031_CR146","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","volume":"62","author":"T Reiberger","year":"2013","unstructured":"Reiberger, T. et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62, 1634\u20131641 (2013).","journal-title":"Gut"},{"key":"1031_CR147","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/apt.12634","volume":"39","author":"E Sinagra","year":"2014","unstructured":"Sinagra, E., Perricone, G., D\u2019Amico, M., Tine, F. & D\u2019Amico, G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment. Pharmacol. Ther. 39, 557\u2013568 (2014).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1031_CR148","first-page":"CD011510","volume":"10","author":"AP Zacharias","year":"2018","unstructured":"Zacharias, A. P. et al. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst. Rev. 10, CD011510 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1031_CR149","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s13318-016-0353-2","volume":"42","author":"MF Rasool","year":"2017","unstructured":"Rasool, M. F., Khalil, F. & Laer, S. Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based pharmacokinetic modeling approach. Eur. J. Drug Metab. Pharmacokinet. 42, 383\u2013396 (2017).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"1031_CR150","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/147323000503300508","volume":"33","author":"H Akbas","year":"2005","unstructured":"Akbas, H. et al. Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury. J. Int. Med. Res. 33, 528\u2013536 (2005).","journal-title":"J. Int. Med. Res."},{"key":"1031_CR151","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.taap.2012.04.012","volume":"261","author":"N Hamdy","year":"2012","unstructured":"Hamdy, N. & El-Demerdash, E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol. Appl. Pharmacol. 261, 292\u2013299 (2012).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1031_CR152","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/apt.16189","volume":"53","author":"HR McDowell","year":"2021","unstructured":"McDowell, H. R. et al. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study. Aliment. Pharmacol. Ther. 53, 531\u2013539 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1031_CR153","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/hep.23045","volume":"50","author":"D Tripathi","year":"2009","unstructured":"Tripathi, D. et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 50, 825\u2013833 (2009).","journal-title":"Hepatology"},{"key":"1031_CR154","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/liv.15559","volume":"43","author":"L Turco","year":"2023","unstructured":"Turco, L., Reiberger, T., Vitale, G. & La Mura, V. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver Int. 43, 1183\u20131194 (2023).","journal-title":"Liver Int."},{"key":"1031_CR155","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/liv.15582","volume":"43","author":"C Villanueva","year":"2023","unstructured":"Villanueva, C. & Tripathi, D. Carvedilol, probably the \u03b2-blocker of choice for everyone with cirrhosis and portal hypertension: but not so fast! Liver Int. 43, 1154\u20131156 (2023).","journal-title":"Liver Int."},{"key":"1031_CR156","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/gutjnl-2016-311735","volume":"66","author":"A Bhardwaj","year":"2017","unstructured":"Bhardwaj, A. et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut 66, 1838\u20131843 (2017).","journal-title":"Gut"},{"key":"1031_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08063-3","volume":"25","author":"VC Patel","year":"2024","unstructured":"Patel, V. C. et al. Beta-blockers or placebo for primary prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial. Trials 25, 265 (2024).","journal-title":"Trials"},{"key":"1031_CR158","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000290","volume":"6","author":"D Tripathi","year":"2019","unstructured":"Tripathi, D. et al. Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial). BMJ Open Gastroenterol. 6, e000290 (2019).","journal-title":"BMJ Open Gastroenterol."},{"key":"1031_CR159","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","volume":"69","author":"J Bosch","year":"2020","unstructured":"Bosch, J., Gracia-Sancho, J. & Abraldes, J. G. Cirrhosis as new indication for statins. Gut 69, 953\u2013962 (2020).","journal-title":"Gut"},{"key":"1031_CR160","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1097\/HEP.0000000000000278","volume":"78","author":"SR Sharpton","year":"2023","unstructured":"Sharpton, S. R. & Loomba, R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC. Hepatology 78, 1896\u20131906 (2023).","journal-title":"Hepatology"},{"key":"1031_CR161","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","volume":"5","author":"E Pose","year":"2020","unstructured":"Pose, E. et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol. Hepatol. 5, 31\u201341 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1031_CR162","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","volume":"46","author":"JG Abraldes","year":"2007","unstructured":"Abraldes, J. G. et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J. Hepatol. 46, 1040\u20131046 (2007).","journal-title":"J. Hepatol."},{"key":"1031_CR163","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","volume":"46","author":"J Trebicka","year":"2007","unstructured":"Trebicka, J. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46, 242\u2013253 (2007).","journal-title":"Hepatology"},{"key":"1031_CR164","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"C Zafra","year":"2004","unstructured":"Zafra, C. et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126, 749\u2013755 (2004).","journal-title":"Gastroenterology"},{"key":"1031_CR165","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"JG Abraldes","year":"2009","unstructured":"Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651\u20131658 (2009).","journal-title":"Gastroenterology"},{"key":"1031_CR166","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","volume":"156","author":"DE Kaplan","year":"2019","unstructured":"Kaplan, D. E. et al. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology 156, 1693\u20131706.e12 (2019).","journal-title":"Gastroenterology"},{"key":"1031_CR167","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/hep.29172","volume":"66","author":"FM Chang","year":"2017","unstructured":"Chang, F. M. et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology 66, 896\u2013907 (2017).","journal-title":"Hepatology"},{"key":"1031_CR168","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","volume":"150","author":"A Mohanty","year":"2016","unstructured":"Mohanty, A., Tate, J. P. & Garcia-Tsao, G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 150, 430\u2013440.e1 (2016).","journal-title":"Gastroenterology"},{"key":"1031_CR169","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/apt.12430","volume":"38","author":"C Motzkus-Feagans","year":"2013","unstructured":"Motzkus-Feagans, C., Pakyz, A. L., Ratliff, S. M., Bajaj, J. S. & Lapane, K. L. Statin use and infections in veterans with cirrhosis. Aliment. Pharmacol. Ther. 38, 611\u2013618 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1031_CR170","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/ajg.2017.170","volume":"112","author":"S Kamal","year":"2017","unstructured":"Kamal, S. et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 112, 1495\u20131505 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"1031_CR171","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","volume":"63","author":"YH Yang","year":"2015","unstructured":"Yang, Y. H. et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J. Hepatol. 63, 1111\u20131117 (2015).","journal-title":"J. Hepatol."},{"key":"1031_CR172","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","volume":"150","author":"JG Abraldes","year":"2016","unstructured":"Abraldes, J. G. et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150, 1160\u20131170.e3 (2016). An important RCT showing the potential of statins in addition to NSBBs in improving survival without impacting rebleeding rates in secondary prophylaxis of variceal bleeding.","journal-title":"Gastroenterology"},{"key":"1031_CR173","doi-asserted-by":"publisher","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","volume":"115","author":"R Vijayaraghavan","year":"2020","unstructured":"Vijayaraghavan, R. et al. Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial. Am. J. Gastroenterol. 115, 729\u2013737 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"1031_CR174","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4254\/wjh.v9.i5.270","volume":"9","author":"ZA Wani","year":"2017","unstructured":"Wani, Z. A., Mohapatra, S., Khan, A. A., Mohapatra, A. & Yatoo, G. N. Addition of simvastatin to carvedilol non responders: a new pharmacological therapy for treatment of portal hypertension. World J. Hepatol. 9, 270\u2013277 (2017).","journal-title":"World J. Hepatol."},{"key":"1031_CR175","doi-asserted-by":"publisher","unstructured":"Alvarado-Tapias, E. et al. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to \u03b2-blockers: a double-blind, placebo-controlled, randomized-trial. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000001148 (2024).","DOI":"10.1097\/HEP.0000000000001148"},{"key":"1031_CR176","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11901-020-00508-y","volume":"19","author":"IR Wanless","year":"2020","unstructured":"Wanless, I. R. The role of vascular injury and congestion in the pathogenesis of cirrhosis: the congestive escalator and the parenchymal extinction sequence. Curr. Hepatol. Rep. 19, 40\u201353 (2020).","journal-title":"Curr. Hepatol. Rep."},{"key":"1031_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030934","volume":"12","author":"N Bitto","year":"2023","unstructured":"Bitto, N., Ghigliazza, G., Lavorato, S., Caputo, C. & La Mura, V. Improving management of portal hypertension: the potential benefit of non-etiological therapies in cirrhosis. J. Clin. Med. 12, e12030934 (2023).","journal-title":"J. Clin. Med."},{"key":"1031_CR178","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11901-023-00598-4","volume":"22","author":"E Felli","year":"2023","unstructured":"Felli, E. et al. Emerging therapeutic targets for portal hypertension. Curr. Hepatol. Rep. 22, 51\u201366 (2023).","journal-title":"Curr. Hepatol. Rep."},{"key":"1031_CR179","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hep.31264","volume":"73","author":"M Serper","year":"2021","unstructured":"Serper, M. et al. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology 73, 219\u2013232 (2021).","journal-title":"Hepatology"},{"key":"1031_CR180","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","volume":"143","author":"E Villa","year":"2012","unstructured":"Villa, E. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143, 1253\u20131260.e4 (2012).","journal-title":"Gastroenterology"},{"key":"1031_CR181","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0168-8278(23)00442-7","volume":"78","author":"AP Sanchez","year":"2023","unstructured":"Sanchez, A. P. et al. Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial. J. Hepatol. 78, S2\u2013S3 (2023).","journal-title":"J. Hepatol."},{"key":"1031_CR182","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome, P. N. & Ambery, P. Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J. Hepatol. 79, 1557\u20131565 (2023).","journal-title":"J. Hepatol."},{"key":"1031_CR183","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR184","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/HEP.0000000000000837","volume":"80","author":"SW Chung","year":"2024","unstructured":"Chung, S. W. et al. Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study. Hepatology 80, 633\u2013648 (2024).","journal-title":"Hepatology"},{"key":"1031_CR185","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/HEP.0000000000000712","volume":"79","author":"A Engstrom","year":"2024","unstructured":"Engstrom, A. et al. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a Scandinavian cohort study. Hepatology 79, 1401\u20131411 (2024).","journal-title":"Hepatology"},{"key":"1031_CR186","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi, M., Rezaeianzadeh, R., Kezouh, A. & Etminan, M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330, 1795\u20131797 (2023).","journal-title":"JAMA"},{"key":"1031_CR187","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cgh.2023.06.004","volume":"22","author":"FS Yen","year":"2024","unstructured":"Yen, F. S. et al. Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes. Clin. Gastroenterol. Hepatol. 22, 1255\u20131264.e18 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR188","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","volume":"382","author":"TG Simon","year":"2020","unstructured":"Simon, T. G. et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N. Engl. J. Med. 382, 1018\u20131028 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR189","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.cgh.2023.03.019","volume":"21","author":"JG Abraldes","year":"2023","unstructured":"Abraldes, J. G., Caraceni, P., Ghabril, M. & Garcia-Tsao, G. Update in the treatment of the complications of cirrhosis. Clin. Gastroenterol. Hepatol. 21, 2100\u20132109 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1031_CR190","doi-asserted-by":"crossref","unstructured":"Albillos, A., Trebicka, J., Bajaj, J. S., Krag, A. & Laleman, W. in Portal hypertension VII (ed. de Franchis, R.) 321\u2013323 (Springer, 2022).","DOI":"10.1007\/978-3-031-08552-9_27"},{"key":"1031_CR191","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12072-021-10135-4","volume":"15","author":"S Selicean","year":"2021","unstructured":"Selicean, S. et al. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol. Intern. 15, 36\u201350 (2021).","journal-title":"Hepatol. Intern."},{"key":"1031_CR192","doi-asserted-by":"publisher","first-page":"101233","DOI":"10.1016\/j.jhepr.2024.101233","volume":"6","author":"S Piano","year":"2024","unstructured":"Piano, S., Reiberger, T. & Bosch, J. Mechanisms and implications of recompensation in cirrhosis. JHEP Rep. 6, 101233 (2024).","journal-title":"JHEP Rep."},{"key":"1031_CR193","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3748\/wjg.v29.i1.61","volume":"29","author":"S Lee","year":"2023","unstructured":"Lee, S. & Saffo, S. Evolution of care in cirrhosis: preventing hepatic decompensation through pharmacotherapy. World J. Gastroenterol. 29, 61\u201374 (2023).","journal-title":"World J. Gastroenterol."},{"key":"1031_CR194","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S2468-1253(23)00438-7","volume":"9","author":"S Guix\u00e9-Muntet","year":"2024","unstructured":"Guix\u00e9-Muntet, S. et al. Pathophysiology and therapeutic options for cirrhotic portal hypertension. Lancet Gastroenterol. Hepatol. 9, 646\u2013663 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1031_CR195","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41575-024-00907-2","volume":"21","author":"M Thiele","year":"2024","unstructured":"Thiele, M. et al. Screening for liver fibrosis: lessons from colorectal and lung cancer screening. Nat. Rev. Gastroenterol. Hepatol. 21, 517\u2013527 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01031-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01031-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01031-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:52:54Z","timestamp":1737985974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01031-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":195,"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1038\/s41575-024-01031-x","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"6 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.V. has received research grant funding from Instituto de Salud Carlos III (ISCiii) and from Vifor. J.B. is supported financially in part by the Swiss Liver Foundation and has been a consultant for Astra Zeneca, Boehringer Ingelheim, Resolution Therapeutics and NovoNordisk. D.T. has received research grant funding from NIHR (National Institute of Health and Care Research), UK, research funding from Boehringer Ingelheim and research funding from AstraZeneca; and is a committee member of the Interventional Procedures Advisory Committee, NICE (National Institute of Health and Care Excellence), UK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}